216 related articles for article (PubMed ID: 35781630)
1. Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406.
Matsukane R; Suetsugu K; Hirota T; Ieiri I
Clin Pharmacokinet; 2022 Jul; 61(7):955-972. PubMed ID: 35781630
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies.
Martin P; Cheung SY; Yen M; Han D; Gillen M
Eur J Clin Pharmacol; 2016 Jan; 72(1):61-71. PubMed ID: 26490353
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies.
Baluom M; Grossbard EB; Mant T; Lau DT
Br J Clin Pharmacol; 2013 Jul; 76(1):78-88. PubMed ID: 23190017
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
Martin P; Gillen M; Millson D; Oliver S; Brealey C; Grossbard EB; Baluom M; Lau D; Sweeny D; Mant T; Craven K
Drugs R D; 2016 Mar; 16(1):81-92. PubMed ID: 26739683
[TBL] [Abstract][Full Text] [Related]
5. Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.
Martin P; Gillen M; Millson D; Oliver S; Brealey C; Elsby R; Baluom M; Lau D; Mant T
Clin Ther; 2015 Dec; 37(12):2811-22. PubMed ID: 26514315
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
Martin P; Oliver S; Gillen M; Marbury T; Millson D
Clin Ther; 2015 Dec; 37(12):2823-36. PubMed ID: 26519231
[TBL] [Abstract][Full Text] [Related]
7. Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia.
Newland A; McDonald V
Immunotherapy; 2020 Dec; 12(18):1325-1340. PubMed ID: 33023353
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs.
Harbi MH; Smith CW; Alenazy FO; Nicolson PLR; Tiwari A; Watson SP; Thomas MR
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805988
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation.
Sweeny DJ; Li W; Clough J; Bhamidipati S; Singh R; Park G; Baluom M; Grossbard E; Lau DT
Drug Metab Dispos; 2010 Jul; 38(7):1166-76. PubMed ID: 20371637
[TBL] [Abstract][Full Text] [Related]
10. Fostamatinib for the treatment of immune thrombocytopenia in adults.
Moore DC; Gebru T; Muslimani A
Am J Health Syst Pharm; 2019 May; 76(11):789-794. PubMed ID: 30951590
[TBL] [Abstract][Full Text] [Related]
11. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
Bussel J; Arnold DM; Grossbard E; Mayer J; Treliński J; Homenda W; Hellmann A; Windyga J; Sivcheva L; Khalafallah AA; Zaja F; Cooper N; Markovtsov V; Zayed H; Duliege AM
Am J Hematol; 2018 Jul; 93(7):921-930. PubMed ID: 29696684
[TBL] [Abstract][Full Text] [Related]
12. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.
Bussel JB; Arnold DM; Boxer MA; Cooper N; Mayer J; Zayed H; Tong S; Duliege AM
Am J Hematol; 2019 May; 94(5):546-553. PubMed ID: 30784097
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
Maringwa J; Kågedal M; Hamrén UW; Martin P; Cox E; Hamrén B
J Clin Pharmacol; 2015 Mar; 55(3):328-35. PubMed ID: 25280085
[TBL] [Abstract][Full Text] [Related]
14. The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells.
Platt AM; Benson RA; McQueenie R; Butcher JP; Braddock M; Brewer JM; McInnes IB; Garside P
Rheumatology (Oxford); 2015 Jan; 54(1):169-77. PubMed ID: 25065010
[TBL] [Abstract][Full Text] [Related]
15. The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.
Skinner M; Philp K; Lengel D; Coverley L; Lamm Bergström E; Glaves P; Musgrove H; Prior H; Braddock M; Huby R; Curwen JO; Duffy P; Harmer AR
Br J Pharmacol; 2014 May; 171(9):2308-20. PubMed ID: 24329544
[TBL] [Abstract][Full Text] [Related]
16. Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib.
Boström E; Öhrn F; Hanze E; Sandström M; Martin P; Wählby-Hamrén U
J Clin Pharmacol; 2014 Dec; 54(12):1337-46. PubMed ID: 24895144
[TBL] [Abstract][Full Text] [Related]
17. Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk.
Mehta AR; Kefela A; Toste C; Sweet D
Acta Haematol; 2022; 145(2):221-228. PubMed ID: 34913873
[TBL] [Abstract][Full Text] [Related]
18. Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients.
Dierickx D; Neefs J
Expert Opin Pharmacother; 2022 Jun; 23(8):885-892. PubMed ID: 35621338
[TBL] [Abstract][Full Text] [Related]
19. Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies.
Flanagan T; Martin P; Gillen M; Mathews D; Lisbon E; Kruusmägi M
Eur J Clin Pharmacol; 2017 Feb; 73(2):185-195. PubMed ID: 27858108
[TBL] [Abstract][Full Text] [Related]
20. Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study.
Jiménez-Bárcenas R; García-Donas-Gabaldón G; Campos-Álvarez RM; Fernández-Sánchez de Mora MC; Luis-Navarro J; Domínguez-Rodríguez JF; Nieto-Hernández MDM; Sánchez-Bazán I; Yera-Cobo M; Cardesa-Cabrera R; Jiménez-Gonzalo FJ; Ruiz-Cobo MA; Caparrós-Miranda I; Entrena-Ureña L; Fernández Jiménez D; Díaz-Canales D; Moreno-Carrasco G; Calderón-Cabrera C; Núñez-Vázquez RJ; Pedrote-Amador B; Mingot-Castellano ME;
Br J Haematol; 2024 May; 204(5):1977-1985. PubMed ID: 38566598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
